Please login to the form below

Not currently logged in
Email:
Password:

inVentiv Health wins Pfizer account

Will be tasked with managing the pharma firm’s global clinical services

inVentiv HealthUS pharmaceutical services organisation inVentiv Health has been named by Pfizer as its preferred provider for global clinical services.

The company will oversee Pfizer's sourcing strategy for the clinical operations of all its worldwide business until June 2019, at which point Pfizer may extend the deal for a further two years.

President of the clinical division at inVentiv Health Dr Michael McKelvy, said: "Complex science and challenging marketplace dynamics are driving the need for new, accelerated approaches to clinical development."

He added: "This agreement is an indication that our leading full-service clinical offerings are value-enhancing and scalable. We designed this approach to deliver patient-centric outcomes in an increasingly competitive environment."

As a result of winning Pfizer's clinical operations account, inVentiv Health expanded its clinical operations, with a focus on oncology, pain, neuroscience and respiratory therapeutic areas as well as data and technology-driven efficiency measures.

Gregory Skalicky, chief commercial officer of inVentiv Health's clinical division, said: "The expansion of our relationship under this new preferred provider status will allow us to continue to seamlessly orchestrate our full suite of clinical solutions.

"We're committed to realising improved efficiencies in support of Pfizer's clinical development activities."

Article by
Rebecca Clifford

29th June 2016

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics